Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as a sterile intravenous solution for intravenous use. It replaces deficient factor IX to restore normal clotting in patients with hemophilia B or other factor IX deficiencies.\n\nGNH India supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Immunine is a recombinant coagulation factor used to manage bleeding disorders related to factor IX deficiency.\n\nHemophilia B: provides replacement of missing factor IX to achieve hemostasis and reduce bleeding episodes.\nFactor IX deficiency: restores adequate clotting activity to prevent spontaneous hemorrhage.\nPeri‑operative management: ensures sufficient factor IX levels for safe surgical or invasive procedures in affected patients.

Immunine may be associated with a range of adverse reactions following intravenous infusion.\n\nCommon Side Effects:\n- Infusion‑related reactions such as fever, chills, or flushing\n- Headache or mild dizziness\n- Nausea or abdominal discomfort\n- Arthralgia or joint pain\n\nSerious or Rare Side Effects:\n- Anaphylactic or severe allergic reactions\n- Development of neutralising antibodies (inhibitors) against factor IX\n- Thrombotic events including deep‑vein thrombosis\n- Hemolysis or renal impairment

Prior to initiating Immunine therapy, clinicians should consider several safety measures.\n\nMonitor for inhibitor development: perform periodic antibody testing to detect neutralising antibodies.\nAssess bleeding risk: evaluate patient history and current anticoagulant use before infusion.\nUse aseptic technique: prepare and administer the product under sterile conditions.\nAvoid in patients with known hypersensitivity: contraindicated for individuals with documented allergy to factor IX products.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine can interact with other medications that affect coagulation or immune response.\n\nMajor Interactions (Avoid):\n- Anticoagulants (e.g., warfarin, heparin): may reduce the efficacy of factor IX replacement.\n- Immune tolerance induction agents: may increase the risk of inhibitor formation.\n\nModerate Interactions (Monitor Closely):\n- Aspirin or NSAIDs: may enhance bleeding tendency despite factor IX supplementation.\n- Antifibrinolytics (e.g., tranexamic acid): may increase risk of thrombosis when combined with factor IX.\n- Vaccines: monitor for heightened immune response or inhibitor development.